clivatuzumab

has antineoplastic activity; structure in first source

Also Known As:

PAM4 antibody; clivatuzumab tetraxetan; hPAM4 antibody

Networked: 12 relevant articles (0 outcomes, 3 trials/studies)

Bio-Agent Context: Research Results

Amino Acids, Peptides, and Proteins: 1
- Proteins: 484843
  - Blood Proteins: 12459
    - Serum Globulins: 553
      - Immunoglobulins: 30480
        Antibodies: 133716
        Monoclonal Antibodies: 56412
        clivatuzumab: 12
    - Immunoproteins: 43
      - Immunoglobulins: 30480
        Antibodies: 133716
        Monoclonal Antibodies: 56412
        clivatuzumab: 12
  - Globulins: 3062
    - Serum Globulins: 553
      - Immunoglobulins: 30480
        Antibodies: 133716
        Monoclonal Antibodies: 56412
        clivatuzumab: 12

Experts

1.	Gold, David V: 5 articles (02/2015 - 04/2004)
2.	Goldenberg, David M: 5 articles (02/2015 - 12/2009)
3.	Chang, Chien-Hsing: 2 articles (02/2015 - 12/2009)
4.	Liu, Donglin: 2 articles (02/2015 - 11/2013)
5.	Karacay, Habibe: 2 articles (06/2011 - 12/2009)
6.	Sharkey, Robert M: 2 articles (06/2011 - 12/2009)
7.	Abushahin, Laith: 1 article (06/2021)
8.	Esnakula, Ashwini: 1 article (06/2021)
9.	Manne, Ashish: 1 article (06/2021)
10.	Tsung, Allan: 1 article (06/2021)

Related Diseases

1.	Pancreatic Neoplasms (Pancreatic Cancer) 06/01/2011 - "Nude mice bearing human pancreatic cancer xenografts (Capan-1 and BxPC-3) were treated with a single dose of 90Y-labeled antimucin antibody (hPAM4; clivatuzumab tetraxetan) alone or in combination with an anti-Trop-2-SN-38 conjugate, typically administered twice weekly over 4 weeks. " 10/01/2001 - "Therapeutic advantage of (90)yttrium- versus (131)iodine-labeled PAM4 antibody in experimental pancreatic cancer." 01/01/2014 - "PAM4, a new monoclonal antibody (MAb) known as clivatuzumab, is highly reactive with pancreatic cancer and precursor lesions. " 11/15/2012 - "Fractionated radioimmunotherapy with (90) Y-clivatuzumab tetraxetan and low-dose gemcitabine is active in advanced pancreatic cancer: A phase 1 trial." 12/01/2010 - "Weekly, Panc-1 and Capan-1 human pancreatic carcinoma xenografts in immunocompromised mice were exposed to an RF field 36 hours after treatment (intraperitoneal) with cetuximab- or PAM4 antibody-conjugated AuNPs, respectively. "
2.	Neoplasms (Cancer) 08/01/2010 - "Investigational drugs discussed include TF-2 plus [68Ga]IMP-288 and TF-2 plus [111In]IMP-288 (both Immunomedics Inc), [11C]PBR-170 (Royal Prince Alfred Hospital/Australian Nuclear Science & Technology Organization), [11C]LY-2795050 (Eli Lilly & Co), yttrium (90Y) clivatuzumab tetraxetan (Garden State Cancer Center/Immunomedics Inc), [18F]LMI-1195 (Lantheus Medical Imaging Inc), fluciclovine (18F) (GE Healthcare/Nihon Medi-Physics Co Ltd), [99mTc]MIP-1340 and [99mTc]MIP-1407 (both Molecular Insight Pharmaceuticals Inc)." 01/01/2015 - "Other 'antibodies to watch' are those in Phase 3 studies with estimated primary completion dates in late 2014 or 2015, which includes 13 for non-cancer indications (brodalumab, bimagrumab, bococizumab, MABp1, gevokizumab, dupilumab, sirukumab, sarilumab, tildrakizumab, guselkumab, epratuzumab, combination of actoxumab + bezlotoxumab, romosozumab) and 2 (racotumomab and clivatuzumab tetraxetan) undergoing evaluation as treatments for cancer. "
3.	Adenocarcinoma 11/20/2013 - "Mapping PAM4 (clivatuzumab), a monoclonal antibody in clinical trials for early detection and therapy of pancreatic ductal adenocarcinoma, to MUC5AC mucin."
4.	Carcinogenesis 06/19/2021 - "NPC-1C and PAM4 antibody reactive epitopes on MUC5AC are immunogenic and could represent specific changes on the native MUC5AC glycoprotein linked to carcinogenesis. "
5.	Pancreatic Ductal Carcinoma 11/15/2012 - "It has been demonstrated that the humanized clivatuzumab tetraxetan (hPAM4) antibody targets pancreatic ductal carcinoma selectively. "

Related Drugs and Biologics

1.	Monoclonal Antibodies
2.	Mucins
3.	Gemcitabine
4.	Antibodies
5.	dupilumab
6.	brodalumab
7.	sirukumab
8.	romosozumab
9.	gevokizumab
10.	epratuzumab

Related Therapies and Procedures

1.	Radioimmunotherapy
2.	Therapeutics
3.	Aftercare (After-Treatment)